By Fineline Cube 
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.
Key Financial Performance
| Division | 2025 Sales (CHF) | USD Equivalent | CER Growth | CHF Growth |
|---|---|---|---|---|
| Group Total | 61.5 billion | 69.1 billion | +7% | +2% |
| Pharmaceuticals | 47.7 billion | 53.6 billion | +9% | — |
| Diagnostics | 13.8 billion | 15.5 billion | +2% | -3% |
Note: All growth figures quoted at constant exchange rates (CER) unless otherwise stated.
Pharmaceutical Growth Drivers
| Product | Indication | 2025 Sales (CHF) | CER Growth |
|---|---|---|---|
| Ocrevus | Multiple sclerosis | 7,010 million | +9% |
| Hemlibra | Hemophilia A | 4,754 million | +11% |
| Vabysmo | Retinal diseases | 4,102 million | +12% |
| Xolair | Severe allergic diseases | 3,075 million | +32% |
| Phesgo | HER2‑positive breast cancer | 2,441 million | +48% |
Combined Impact: These five products generated CHF 21.4 billion in sales, accounting for a CHF 3.2 billion CER increase year‑on‑year.
Regional Performance & China Market
- United States: Pharmaceuticals sales +8%, driven by Ocrevus and Hemlibra
- Europe & Japan: Both regions delivered +5% growth
- International (including China): +14% overall, with China +10% supported by NRDL inclusion of Phesgo and uptake of Xofluza, Vabysmo, and Polivy
- Diagnostics Asia‑Pacific: Declined 12%, reflecting China healthcare pricing reforms
Pipeline Progress & 2026 Outlook
2025 Milestones:
- US & EU approvals for subcutaneous Lunsumio in follicular lymphoma
- EU approval of Gazyva for lupus nephritis
- Positive data for SERD giredestrant in ER‑positive breast cancer and BTK inhibitor fenebrutinib in multiple sclerosis
- 10 molecules advanced to Phase III development
2026 Guidance: Roche expects mid‑single‑digit sales growth and high‑single‑digit core EPS growth at CER.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding 2026 guidance, pipeline development, and market growth. Actual results may differ due to competitive dynamics, pricing pressures, and macroeconomic factors.-Fineline Info & Tech